# Genesis Capital

> Genesis Capital is a VC fund in Central backing Biotechnology and Artificial Intelligence. See 39 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 39
- Last investment: Jul 2026
- Lead investor: 56%
- Fund size: $850M
- Last fund: Jul 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/10846047/
- Website: http://www.gcfunds.com/en/

Genesis Capital is a VC fund in Central focused on Biotechnology and Artificial Intelligence. Genesis Capital, founded in 2015 by Richard Peng, former corporate Vice President and Head of Investment of Tencent, and Kurt Xu, former Vice General Manager of Investment of Tencent, is a growth capital fund exclusively focused on growth stage Internet companies. We currently manage a USD fund and a RMB fund. We leverage our unparalleled industryexperience to provide critical support to our portfolio companies at critical moments. Together we change the world with great entrepreneurs.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 21% |
| Artificial Intelligence | 6 | 15% |
| Health Care | 4 | 10% |
| Pharmaceutical | 4 | 10% |
| Medical | 3 | 8% |

51 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 28% |
| Series B | 10 | 26% |
| Series C | 7 | 18% |
| Seed | 3 | 8% |
| Series D | 2 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 27 | 69% |
| United States | 2 | 5% |
| Canada | 1 | 3% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Looki | Looki is building the next generation of human-centric ai platforms - emotionally aware, and deeply embedded in the physical world. |  | Series A | Jul 14, 2026 |  |
| VAST | VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $147.3M | Series A | Jul 02, 2026 |  |
| VAST | VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $200M | Series A | Jun 01, 2026 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $63M | Series B | Sep 21, 2025 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $50.3M | Series B | May 28, 2025 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $37M | Series A | Jul 14, 2024 |  |
| Xunjie Guangyuan | Xunjie Guangyuan operates engages in the research and development of near-infrared spectroscopy analysis instruments. | $14.1M | Series A | May 30, 2024 |  |
| Qcraft | Qcraft operates as a self-driving startup company. Qcraft develops AV simulation testing, which refers to a system solution that trains self-driving cars to deal with vast traffic scenarios, especially unusual cases, on a virtual road network. |  | Series B | Dec 02, 2022 |  |
| ZVISION | Zvision provides automotive-grade solid-state LiDAR solution for autonomous driving applications. The company's first-generation laser radar products use MEMS technology, and plan to achieve scale-up in the L3-class autonomous driving and unmanned logistics fields in the next five years, and layout the next generation optical-based phasedarray (OPA) through its integrated chip research and development capabilities. The technical laser radar is aimed at the L4/L5 level autopilot market after 5-10 years. |  | Series C | Nov 16, 2022 |  |
| CATUG Biotechnology | CATUG is focused on the development and application of new biomedical technologies. It provides one-stop CDMO services for the entire industry chain from quality research and clinical application to industrialization. It has R&D centers and industrialization bases in Suzhou and Wuhan. |  | Series A | Apr 25, 2022 |  |

10 of 39 investments shown.

## Co-investors
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 10 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 6 deals together
- [Eastern Bell Capital](https://shizune.co/investors/profile/eastern-bell-venture-capital) — VC Fund, 5 deals together
- [Yuansheng Capital](https://shizune.co/investors/profile/yuansheng-capital) — VC Fund, 5 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 4 deals together
- [BAI capital](https://shizune.co/investors/profile/bertelsmann-asia-investments) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Blockchain Investors in China](https://shizune.co/investors/blockchain-investors-china)
- [Life Science Investors in China](https://shizune.co/investors/life-science-investors-china)
- [Life Science VC Funds in China](https://shizune.co/investors/life-science-vc-funds-china)

## FAQ

### What does Genesis Capital invest in?

Genesis Capital invests primarily in Biotechnology, Artificial Intelligence and Health Care startups, most often at Series A and Series B stage. Most of the 39 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Genesis Capital last invest?

The most recent investment recorded for Genesis Capital closed in Jul 2026. Shizune tracks 39 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co